Background Type 2 diabetes is associated with a substantially increased risk of cardiovascular
disease, but the role of lipid-lowering therapy with statins for the primary prevention of …

Background Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to
reduce the risk of adverse cardiovascular events in patients with diabetes. Whether …

Background Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce
cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk with high …

Inability to replicate many results has led to increasing scepticism about the value of simple
association study designs for detection of genetic variants contributing to common complex …

Context The associations of low-density lipoprotein cholesterol (LDL-C), non–high-density
lipoprotein cholesterol (non–HDL-C), and apolipoprotein B (apoB) levels with the risk of …

Background : Levels of atherogenic lipoproteins achieved with statin therapy are highly
variable, but the consequence of this variability for cardiovascular disease risk is not well-…

Importance Type 1 diabetes has historically been associated with a significant reduction in
life expectancy. Major advances in treatment of type 1 diabetes have occurred in the past 3 …

… Helen M. Colhoun, Ph.D. … Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose
administration and the influence of the timing of the booster dose on immunogenicity and …

Background We aimed to ascertain the cumulative risk of fatal or critical care unit-treated
COVID-19 in people with diabetes and compare it with that of people without diabetes, and to …

Background Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal outcomes
in people with type 2 diabetes at risk for cardiovascular disease. We assessed the long-…